Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ambit Biosciences
San Diego, California, United Statesambitenergy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ambit's lead asset quizartinib showed promise in treating relapsed/refractory AML patients with FLT3 mutations—a population with poor prognosis and limited treatment options. The company had three internally developed programs at the time of acquisition. Quizartinib was considered a potential first-in-class therapy for this indication and drove Daiichi Sankyo's interest in the acquisition
- Therapeutic areas
- OncologyImmunology
- Modalities
- small molecules (kinase inhibitors)
- Industry
- Biotech
02
Partnerships
No major external pharma partnerships reported prior to acquisition.Financial advisors included Centerview Partners and Leerink Partners LLC during M&A process.Legal advisors included Cooley LLP.
Beyond the preview
Go deeper on Ambit Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambit Biosciences.